NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02117479 2019-03-26Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)Incyte CorporationPhase 3 Terminated321 enrolled 13 charts
NCT02119663 2018-02-13A Study of Ruxolitinib in Pancreatic Cancer PatientsIncyte CorporationPhase 3 Terminated86 enrolled 12 charts
NCT01822756 2018-02-12An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid TumorsIncyte CorporationPhase 1 Terminated42 enrolled 14 charts